Cargando…

Accurate In-Vivo Quantification of CD19 CAR-T Cells after Treatment with Axicabtagene Ciloleucel (Axi-Cel) and Tisagenlecleucel (Tisa-Cel) Using Digital PCR

Immunotherapy with CD19-specific chimeric antigen receptor (CAR-) T cells has shown excellent efficacy in relapsed/refractory B-cell cancers. The in vivo expansion and persistence of CAR-T cells after infusion are important response- and toxicity-determining variables, but diagnostic tools are large...

Descripción completa

Detalles Bibliográficos
Autores principales:	Badbaran, Anita, Berger, Carolina, Riecken, Kristoffer, Kruchen, Anne, Geffken, Maria, Müller, Ingo, Kröger, Nicolaus, Ayuk, Francis A., Fehse, Boris
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409173/ https://www.ncbi.nlm.nih.gov/pubmed/32698364 http://dx.doi.org/10.3390/cancers12071970

Ejemplares similares

Digital PCR Assays for Precise Quantification of CD19-CAR-T Cells after Treatment with Axicabtagene Ciloleucel
por: Fehse, Boris, et al.
Publicado: (2020)

P1398: AXICABTAGENE CILOLEUCEL VERSUS TISAGENLECLEUCEL CAR-T CELLS IN RELAPSED OR REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
por: Gagelmann, Nico, et al.
Publicado: (2023)

Assessment of CAR T Cell Frequencies in Axicabtagene Ciloleucel and Tisagenlecleucel Patients Using Duplex Quantitative PCR
por: Schubert, Maria-Luisa, et al.
Publicado: (2020)

Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma
por: Kwon, Mi, et al.
Publicado: (2022)

A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma
por: Bachy, Emmanuel, et al.
Publicado: (2022)

Efficacy, safety, and cost-minimization analysis of axicabtagene ciloleucel and tisagenlecleucel CAR T-Cell therapies for treatment of relapsed or refractory follicular lymphoma
por: Ghanem, Buthainah
Publicado: (2023)

P1111: COMPARATIVE EFFICACY AND SAFETY OF TISAGENLECLEUCEL AND AXICABTAGENE CILOLEUCEL IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
por: Dickinson, M., et al.
Publicado: (2022)

P1203: EFFICACY AND SAFETY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) FOR THE TREATMENT OF RELAPSE/REFRACTORY NON-HODGKIN LYMPHOMA: FIRST REAL-WORLD DATA IN CHINESE POPULATION
por: Wang, LI, et al.
Publicado: (2023)

Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis
por: Meng, Jun, et al.
Publicado: (2021)

Efficacy and Safety of Axicabtagene Ciloleucel and Tisagenlecleucel Administration in Lymphoma Patients With Secondary CNS Involvement: A Systematic Review
por: Wu, XiaoQin, et al.
Publicado: (2021)

Corrigendum: Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis
por: Meng, Jun, et al.
Publicado: (2021)

Axicabtagene ciloleucel for B-cell lymphoma
Publicado: (2021)

Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Tisagenlecleucel for the Management of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Spain
por: Bastos-Oreiro, Mariana, et al.
Publicado: (2022)

Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
por: Choe, Jee H., et al.
Publicado: (2022)

P1197: AXICABTAGENE CILOLEUCEL (AXI-CEL) IN COMBINATION WITH RITUXIMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): OUTCOMES OF THE PHASE 2 ZUMA-14 STUDY
por: Strati, P., et al.
Publicado: (2022)

Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry study
por: Schubert, Maria-Luisa, et al.
Publicado: (2023)

Mar cel Levi
por: Baltesen, Frits
Publicado: (2021)

Pathogenic Carboxyl Ester Lipase (CEL) Variants Interact with the Normal CEL Protein in Pancreatic Cells
por: Dalva, Monica, et al.
Publicado: (2020)

Axicabtagene Ciloleucel: The First FDA-Approved CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
por: King, Amber C., et al.
Publicado: (2019)

Predictors of response to axicabtagene‐ciloleucel CAR T cells in aggressive B cell lymphomas: A real‐world study
por: Iovino, Lorenzo, et al.
Publicado: (2022)

Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States
por: Parker, Christopher, et al.
Publicado: (2023)

Safety and efficacy of axicabtagene ciloleucel in refractory large B-cell lymphomas
por: Riedell, Peter A., et al.
Publicado: (2020)

Expression, Characterization and Synergistic Interactions of Myxobacter Sp. AL-1 Cel9 and Cel48 Glycosyl Hydrolases
por: Ramírez-Ramírez, Norma, et al.
Publicado: (2008)

Comparison of single copy gene-based duplex quantitative PCR and digital droplet PCR for monitoring of expansion of CD19-directed CAR T cells in treated patients
por: Schubert, Maria-Luisa, et al.
Publicado: (2022)

P1694: COST-EFFECTIVENESS OF AXICABTAGENE CILOLEUCEL VS. TISAGENLECLEUCEL FOR THE TREATMENT OF RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA: UPDATED SURVIVAL RESULTS FROM THE ZUMA-1 AND JULIET TRIALS
por: Oluwole, Olalekan, et al.
Publicado: (2023)

Acute patient‐reported outcomes in B‐cell malignancies treated with axicabtagene ciloleucel
por: Hoogland, Aasha I., et al.
Publicado: (2021)

Cel i terra : l'art dels cartógrafs a la Universitat de Valéncia /
Publicado: (1996)

P1169: ELEVATED CRP AT INFUSION OF AXICABTAGENE CILOLEUCEL PREDICTS HIGH-GRADE CAR-T TOXICITY AND OUTPERFORMS MORE COMPLEX SCORES
por: Boyle, S., et al.
Publicado: (2022)

Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma
por: Maloney, David G., et al.
Publicado: (2021)

Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma
por: Oluwole, Olalekan O., et al.
Publicado: (2021)

The role of axicabtagene ciloleucel as a treatment option for patients with follicular/marginal zone lymphoma
por: Sandoval-Sus, Jose, et al.
Publicado: (2021)

S223: REAL-WORLD EARLY OUTCOMES OF AXICABTAGENE CILOLEUCEL FOR RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
por: Jacobson, Caron, et al.
Publicado: (2023)

Catalytic Mechanism of Cellulose Degradation by a Cellobiohydrolase, CelS
por: Saharay, Moumita, et al.
Publicado: (2010)

Hypocrea jecorina CEL6A protein engineering
por: Lantz, Suzanne E, et al.
Publicado: (2010)

Regulation of cel Genes of C. cellulolyticum: Identification of GlyR2, a Transcriptional Regulator Regulating cel5D Gene Expression
por: Fendri, Imen, et al.
Publicado: (2013)

Molecular and biochemical characterization of recombinant cel12B, cel8C, and peh28 overexpressed in Escherichia coli and their potential in biofuel production
por: Ibrahim, Eman, et al.
Publicado: (2017)

Chimeric antigen receptor (CAR) T-cell therapy as a treatment option for patients with B-cell lymphomas: perspectives on the therapeutic potential of Axicabtagene ciloleucel
por: Viardot, Andreas, et al.
Publicado: (2019)

Metabolic PET/CT analysis of aggressive Non-Hodgkin lymphoma prior to Axicabtagene Ciloleucel CAR-T infusion: predictors of progressive disease, survival, and toxicity
por: Breen, William G., et al.
Publicado: (2023)

Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma
por: Strati, Paolo, et al.
Publicado: (2020)

Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response
por: Jallouk, Andrew P., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_78daj4bcq83gp0pjrfqnubv1rk